Streetbeat News

EXAI

Exscientia plc

https://www.exscientia.ai

Industry

Biotechnology

Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Exscientia reported its Q2 2024 financial results with a GAAP EPS of $(0.36), which is not comparable to the $(0.17) estimate. The company also reported sales of $5.6 million, which is not comparable to the $12.942 million estimate.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 11:04 am

Barclays analyst Peter Lawson has downgraded Exscientia (NASDAQ:EXAI) from Overweight to Equal-Weight and set a price target of $5.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 5:34 pm

TD Cowen analyst Brendan Smith has downgraded Exscientia (NASDAQ:EXAI) from Buy to Hold.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 10:38 am

Exscientia plc (NASDAQ:EXAI) will merge with Recursion Pharmaceuticals Inc. (NASDAQ:RXRX), with Exscientia shareholders receiving 0.7729 Recursion shares for each Exscientia share. The combined entity will be named Recursion, headquartered in Salt Lake City, and will trade on NASDAQ. The merger aims to enhance drug discovery capabilities and expects significant synergies and clinical trial readouts in the next 18 months.

Portfolio Pulse from Vandana Singh

August 08, 2024 | 9:37 pm

Recursion Pharmaceuticals (RXRX) and Exscientia (EXAI) have announced a definitive agreement to combine their capabilities to create a leading end-to-end drug discovery platform. The collaboration is expected to yield 10 clinical readouts in the next 18 months, $200 million in milestone payments over 24 months, and potentially $20 billion overall. The companies have $850 million in cash on hand and anticipate $100 million in annual synergies.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:40 am

Barclays analyst Peter Lawson maintains an Overweight rating on Exscientia (NASDAQ:EXAI) but lowers the price target from $10 to $9.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 3:27 pm

Exscientia has agreed to acquire GT Apeiron's share of its oral CDK7 inhibitor program, gaining full control of GTAEXS617 and all related intellectual property. Exscientia will pay GT Apeiron $10 million upfront in cash and $10 million in equity, and will take on all existing development costs. The monotherapy dose escalation phase of the ELUCIDATE trial is progressing well, with data expected in the second half of 2024. Exscientia's cash runway is expected to extend well into 2027.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 11:04 am

Exscientia shares are trading lower after the company reported worse-than-expected Q1 sales results.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 3:38 pm

Exscientia reported cash, cash equivalents, and short-term bank deposits of $416.9 million as of March 31, 2024, which is expected to provide a cash runway into 2027.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:06 am

Exscientia reported a Q1 2024 GAAP EPS of $(0.21), beating the estimate of $(0.39). However, its sales of $6.7M missed the estimate of $7.509M.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:03 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.